A team of scientists from Ontari UniversityOr, in Canada, the end The third phase of the clinical test tablet for weight loss This can resist OvorpikThe field is about Orforgliprona medicine that is actually quite a lot connected With this. Both are what is known as the GLP-1 agonist, but there are rather important differences.
It can be assumed that both Overpik and this tablet for weight loss are similar. However, the main difference is precisely the format. While the agonists of the Ovorpik and other LPG-1 agonists are available on the market, for example, as WegovyThey are managed injectionsOrforglipron mainly TabletThe field administration is much more convenient, much less patients refuse treatment.
And although those who take these medicines often do this with the desire to lose weight, there are many people who have Needle panicIn addition, this is not only a matter of fear. Patients may not know how to adequately introduce and need the help of other people. In this case, if you take a tablet to lose weight, this is enough. The boat is soon, they seem to be all the advantages. Let’s see what was noticed with Clinical test.
Before starting, what are the GLP-1 agonists, such as Overpik?
LPG-1 agonists are fashionable. These are medicines that imitate the influence Peptide, similar to type 1 glucagon (LPG-1)The hormone, which is naturally secreted in our body, usually when we eat. It has two main functions. On the one side, stimulates insulin synthesis Control the level of glucose in the blood. And, on the other hand, it causes a feeling of satiety Through mechanisms, such as emptying the stomach. Thus, since we just ate, we will not be desirable to do it again until it is needed.
The natural problem of SNPG-1 is that it weakens very quickly, so its effects are quite durable. Therefore, in recent years, some drugs have been studied that act as agonists, Imitating his consequencesBut for a longer period of time. One of those GLP-1 agonists is the famous Ogrokek, whose role initially had nothing to do with weight loss.
Its use is usually aimed at Patients with diabetesSince this helps to control blood glucose in several different ways. However, in the control of appetite, also helping Weight loss. This made the ORITARY start to widely use for this purpose, even causing Lack In the pharmacies of some countries. This is something dangerous, because patients with diabetes who really needed medicines began to end. Therefore, other similar drugs began to study in order to put them on the market for the sole purpose of weight loss. It would be a case of this tablet to lose weight. Clinical trials ended with very positive results, so we are not so much time to get it.
How does slip tablets work?
The mechanism of this tablet for weight loss is exactly the same as that of Overpik. Imitate the LPG-1- mechanism. But is it equally effective?
To answer this question, scientists from the University of Ontario launched Multinational clinical studies, randomized and double blindThis means that it was carried out with patients from many countries, and that half of them received the medicine randomly, and the rest took a placebo. Neither researchers nor volunteers knew who accepted the pill to lose weight and who the placebo. Thus, the results obtained from the sentence are avoided. This is what is known as a double blind.
In total, at the stage of 3 clinical trials, they took part 3127 patients Based on The United States, China, Brazil, India, Japan, South Korea, Spain, Slovakia and Taiwan. They all had Obesity, but without type 2 diabetesA field to conduct a clinical test, they took a tablet per day for 72 weeks. Half took placebo tablets, and the rest – tablets for weight loss. In the latter case, I could contain 6, 12 or 36 mg Orforglipron.
How much did they lose weight from Orforglipron?
The average relative change in body weight from the very beginning to 72 weeks was -7.5% with 6 mg orforglipron, -8.4% with 12 mg and -11.2% with 36 mg of weight loss tablets. Instead, those who took the placebo is lost on average 2.1 % of weight. It should be noted that everyone supported Healthy diet and physical exercises. That is why he also thinned out with a placebo.
As for the most radical results, it was noticed that among patients Orforglipron Group 36 mg, 54.6% had a decrease of 10% or more body weight, by 36% a decrease of 15% or more and by 18.4% by 20% or more decreaseThe field for the placebo group was 12.9%, 5.9% and 2.8%, respectively.
Were there side effects with weight loss?
Yes, there were side effects, but they were Pretty insignificantUsually digestive and no worse than other GLP-1 agonists. Therefore, it is concluded that this tablet for weight loss is a safe and effective drug, which is also administered in a simple way for all patients. There were fewer treatment failures than usual with Injection drugs.
Since stage 3 of clinical trials is the last that is usually performed before the launch of the medicine for pharmacies, it seems that this is very good. Typically, phase 4 is performed with possible incidents (or their absence) of all patients who take drugs after reaching pharmacies. This is what is known as Observation postcomfilization.
In any case, to get to this bureaucracy. In any case, there may not be enough so much for a long tablet to lose weight that so many people were waiting. So far this does not happen, remember that with healthy nutrition and physical exercises you can also achieve great things.
Source: Hiper Textual
